• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?雌激素受体（ER）阳性乳腺癌患者中的HER2阳性：它真的具有预后价值吗？
Breast. 2021 Feb;55:136. doi: 10.1016/j.breast.2020.11.017. Epub 2020 Nov 30.
2
High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.高Ki-67表达和低孕激素受体表达可独立导致雌激素受体阳性且人表皮生长因子受体2阴性的绝经后乳腺癌患者预后较差。
Clin Breast Cancer. 2015 Jun;15(3):204-11. doi: 10.1016/j.clbc.2014.12.007. Epub 2014 Dec 24.
3
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.雌激素或孕激素受体阴性表达在腔面B型HER2阴性乳腺癌患者中的预后价值
World J Surg Oncol. 2016 Sep 13;14(1):244. doi: 10.1186/s12957-016-0999-x.
4
Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.PgR表达作为通过Ki67标记指数分类的中度风险ER阳性/HER2阴性乳腺癌患者预后因素的作用。
BMC Cancer. 2017 May 22;17(1):354. doi: 10.1186/s12885-017-3331-4.
5
Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.拓扑异构酶 II alpha 表达和 Ki-67 标记指数与雌激素受体阳性和人表皮生长因子受体 2 阴性乳腺癌的预后因素相关。
Breast Cancer. 2012 Oct;19(4):309-14. doi: 10.1007/s12282-011-0291-4. Epub 2011 Jul 2.
6
Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.mTOR/S6K而非MAPK信号通路的激活可能与高Ki-67、雌激素受体阳性（ER(+)）及人表皮生长因子受体2阴性（HER2(-)）乳腺癌相关。
Clin Breast Cancer. 2015 Jun;15(3):197-203. doi: 10.1016/j.clbc.2014.12.002. Epub 2014 Dec 24.
7
Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.乳腺癌中HER2表达与其他预后因素的相关性：与Ki-67指数和P53状态呈负相关。
Asian Pac J Cancer Prev. 2016;17(3):1015-8. doi: 10.7314/apjcp.2016.17.3.1015.
8
Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.保乳手术后最大直径小于或等于 2cm 的乳腺癌免疫组化定义亚型的长期预后
J Surg Res. 2019 Apr;236:288-299. doi: 10.1016/j.jss.2018.11.028. Epub 2018 Dec 27.
9
A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.基于新辅助化疗后雌激素受体表达和 Ki-67 值相结合的预后模型预测局部晚期乳腺癌的临床结局：对先前报道的患者队列的扩展和分析。
Eur J Surg Oncol. 2013 Oct;39(10):1046-52. doi: 10.1016/j.ejso.2013.06.024. Epub 2013 Jul 26.
10
Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.在雌激素受体阳性/HER2 阴性已行手术的乳腺癌中，肿瘤浸润淋巴细胞的预后意义可能因 Ki67 表达水平而异。
Breast Cancer. 2019 Nov;26(6):738-747. doi: 10.1007/s12282-019-00977-0. Epub 2019 May 16.

本文引用的文献

1
HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab.在接受化疗和曲妥珠单抗治疗的高危雌激素受体阳性早期乳腺癌患者中，HER2 阳性与不良预后无关。
Breast. 2020 Dec;54:235-241. doi: 10.1016/j.breast.2020.10.002. Epub 2020 Oct 15.
2
Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.根据激素受体和 Her2 免疫组化确定的不同肿瘤亚型，乳腺癌患者的生存和临床病理特征。一项跨越 1998 年至 2010 年的单机构调查。
Breast. 2012 Jun;21(3):366-73. doi: 10.1016/j.breast.2012.03.004. Epub 2012 Apr 7.
3
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.激素受体阳性的绝经前原发性乳腺癌中的HER2状态可提供预后信息，但不能预测他莫昔芬的治疗效果。
Breast Cancer Res Treat. 2008 May;109(2):351-7. doi: 10.1007/s10549-007-9660-2. Epub 2007 Jul 18.
4
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.他莫昔芬耐药机制：雌激素受体与HER2/neu在ER/HER2阳性乳腺癌中相互作用增强
J Natl Cancer Inst. 2004 Jun 16;96(12):926-35. doi: 10.1093/jnci/djh166.

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?

作者信息

Batra Atul, Kumar Akash

机构信息

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Breast. 2021 Feb;55:136. doi: 10.1016/j.breast.2020.11.017. Epub 2020 Nov 30.

DOI:10.1016/j.breast.2020.11.017
PMID:33328129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7878443/
Abstract
摘要